Intranasal immunization with a rNMB0315 and combination adjuvants induces protective immunity against Neisseria meningitidis serogroup B in mice

Li, Zhenyu; Li, Yumeng; Wang, Yan; Hou, YongLi; Cao, Hui; Wu, Xiaoxia; Hu, Sihai; Long, Dongyang

doi:10.1016/j.intimp.2021.107411

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 . Poly(I:C) and CpG ODN adjuvants have previously been shown to boost induction and generation of antibody levels, and were used in this experiment [ 19 - 21 ].…”

Section: Resultsmentioning

confidence: 99%

Nasal Immunization Using Chitosan Nanoparticles with Glycoprotein B of Murine Cytomegalovirus

Slovakova,

Janovska,

Sleha

et al. 2023

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

The use of nanoparticles as a delivery system for a specific antigen could solve many limitations of mucosal vaccine applications, such as low immunogenicity, or antigen protection and stabilization. In this study, we tested the ability of nasally administered chitosan nanoparticles loaded with glycoprotein B of murine cytomegalovirus to induce an immune response in an animal model. The choice of chitosan nanoparticle type was made by in vitro evaluation of sorption efficiency and antigen release. Three types of chitosan nanoparticles were prepared: crosslinked with tripolyphosphate, coated with hyaluronic acid, and in complex with polycaprolactone. The hydrodynamic size of the nanoparticles by dynamic light scattering, zeta potential, Fourier transform infrared spectroscopy, scanning electron microscopy, stability, loading efficiency, and release kinetics with ovalbumin were evaluated. Balb/c mice were immunized intranasally using the three-dose protocol with nanoparticles, gB, and adjuvants Poly(I:C) and CpG ODN. Subsequently, the humoral and cell-mediated antigen-specific immune response was determined. On the basis of the properties of the tested nanoparticles, the cross-linked nanoparticles were considered optimal for further investigation. The results show that nanoparticles with Poly(I:C) and with gB alone raised IgG antibody levels above the negative control. In the case of mucosal IgA, only gB alone weakly induced the production of IgA antibodies compared to saline-immunized mice. The number of activated cells increased slightly in mice immunized with nanoparticles and gB compared to those immunized with gB alone or to negative control. The results demonstrated that chitosan nanoparticles could have potential in the development of mucosal vaccines.

show abstract

“…5 . Poly(I:C) and CpG ODN adjuvants have previously been shown to boost induction and generation of antibody levels, and were used in this experiment [ 19 - 21 ].…”

Section: Resultsmentioning

confidence: 99%

Nasal Immunization Using Chitosan Nanoparticles with Glycoprotein B of Murine Cytomegalovirus

Slovakova,

Janovska,

Sleha

et al. 2023

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…For example, the combination adjuvants AS04 and AS01B have been approved for use in humans by the FDA and have enhanced the immunogenicity of intranasal vaccines, as confirmed in various studies ( Couch et al, 2009 ; Hirano et al, 2011 ; Blanco et al, 2014 ). Immunopotentiators (CpG-ODN or C48/80) were loaded into mucoadhesive polymer (chitosan) to form a combination adjuvant and were adopted to enhance the immunogenicity of the intranasal vaccine in mice ( Li et al, 2021 ). The combination adjuvant comprised of polymer nanoparticles (dendrimer-like alpha-d-glucan) and Poly I:C can enhance the mucosal immune response and systemic responses to intranasal inactivated influenza vaccine in pigs ( Renu et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Hua

Chang²,

Zhang³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Pseudorabies virus (PRV) not only causes great economic loss to the pig industry but also seriously threatens the biosafety of other mammals, including humans. Since 2011, PRV mutant strains have emerged widely in China, and the classical Bartha-K61 vaccine cannot confer complete protection for pigs. PRV mainly infects pigs via the respiratory tract. Intranasal immunization with PRV has received more attention because intranasal vaccination elicits systemic and mucosal immune responses. To induce systemic and mucosal immune responses against PRV, we developed a combination adjuvant as a delivery system for intranasal vaccine, which was formulated with MONTANIDE™ Gel 01 and CVCVA5. In comparison to naked antigen of inactivated PRV, single Gel 01 adjuvanted inactivated antigen and single CVCVA5 adjuvanted inactivated antigen, intranasal inactivated PRV vaccine formulated with the combination adjuvant induced greater mucosal IgA immunity and serum antibody responses (IgG, IgG1, and IgG2a). Furthermore, the production of the Th1-type cytokine IFN-γ and the Th2-type cytokine IL-4 indicated that the cellular and humoral responses to the intranasal vaccine were improved by the combination adjuvant. In addition, the intranasal vaccine formulated with the combination adjuvant induced long-term T lymphocyte memory with increased central (CD62L+CD44+) and effector (CD62L–CD44+) memory subsets of both CD4 and CD8 T cells in nasal-associated lymphoid tissue. Intranasal challenge with virulent PRV in mice showed that the protective efficacy of the intranasal PRV vaccine was improved by the combination adjuvant compared with the other single-adjuvanted vaccines. In summary, these data demonstrated that Gel 01 combined with the CVCVA5 adjuvant induced a synergistic effect to improve mucosal immunity and protective efficacy of the intranasally inactivated PRV vaccine in mice. It represents a promising vaccination approach against PRV infection.

show abstract

Study of avidity-ELISA: Comparison of chaotropic agents, incubation temperature and affinity maturation after meningococcal immunization

Portilho

Santos

Lima

et al. 2023

Journal of Immunological Methods

View full text Add to dashboard Cite

Intranasal immunization with a rNMB0315 and combination adjuvants induces protective immunity against Neisseria meningitidis serogroup B in mice

Cited by 5 publications

References 30 publications

Nasal Immunization Using Chitosan Nanoparticles with Glycoprotein B of Murine Cytomegalovirus

Nasal Immunization Using Chitosan Nanoparticles with Glycoprotein B of Murine Cytomegalovirus

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Study of avidity-ELISA: Comparison of chaotropic agents, incubation temperature and affinity maturation after meningococcal immunization

Contact Info

Product

Resources

About